Table 2 Clinical Characteristics of the Patients by Treatment Groups
From: Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial
Characteristics | All patients (n = 100) | Arbidol group (n = 50) | KALETRA group (n = 50) | P Value |
|---|---|---|---|---|
Signs and Symptoms, n (%) | ||||
Fever | 46 (46) | 19 (38) | 27 (54) | 0.1 |
Cough | 80 (80) | 41 (82) | 39 (78) | 0.6 |
Shortness of breath | 66 (66) | 33 (66) | 33 (66) | 0.99 |
Weakness | 61 (61) | 35 (70) | 26 (52) | 0.6 |
Anosmia | 10 (10) | 6 (12) | 4 (8) | 0.5 |
Diarrhea | 15 (15) | 12 (24) | 3 (6) | 0.01 |
Nausea and vomiting | 26 (26) | 11 (22) | 15 (30) | 0.3 |
Myalgia | 45 (45) | 20 (40) | 25 (50) | 0.3 |
Headache | 17 (17) | 13 (26) | 4 (8) | 0.01 |
Others | 50 (50) | 18 (36) | 32 (64) | 0.005 |
Hospitalization location, n (%) | 88 (100) | 43 (100) | 45 (100) | 0.09 |
ICU, n (%) | 43 (48.8) | 8 (18.6) | 3 (6.7) | |
Ward, n (%) | 45 (51.1) | 35 (81.4) | 42 (93.3) | |
Hospitalization duration, days (SD) | 8.4 (5.1) | 7.2 (4.7) | 9.6 (5.2) | 0.02 |
Time to stop fever, days (SD) | 2.9 (1.3) | 2.7 (1.1) | 3.1 (1.4) | 0.2 |
Illness severity, n (%) | 0.9 | |||
Mild | 19 (19) | 9 (18) | 10 (20) | |
Moderate | 58 (58) | 29 (58) | 29 (58) | |
Severe | 23 (23) | 12 (24) | 11 (22) | |
CT scan in beginning, n (%) | 100 (100) | 50 (100) | 50 (100) | 0.9 |
Involvement type, n (%) | ||||
Mild | 11 (11) | 5 (10) | 6 (12) | |
Moderate | 66 (66) | 33 (66) | 33 (66) | |
severe | 23 (23) | 12 (24) | 11 (22) | |
CT scan in 30th day, n (%) | 97 (100) | 49 (100) | 48 (100) | 0.004 |
Involvement type, n (%) | ||||
Mild | 63 (64.9) | 38 (80.9) | 25 (53.2) | |
Moderate | 31 (31.9) | 9 (19.1) | 22 (46.8) | |
severe | 0 (0) | 0 (0) | 0 | |
CXR in beginning, n (%) | 100 (100) | 50 (100) | 50 (100) | 0.3 |
Involvement type, n (%) | ||||
Mild | 25 (25) | 11 (22) | 14 (28) | |
Moderate | 66 (66) | 36 (72) | 30 (60) | |
severe | 9 (9) | 3 (6) | 6 (12) | |
CXR in 30th day, n (%) | 97 (100) | 49 (100) | 48 (100) | < 0.001 |
Involvement type, n (%) | ||||
Mild | 75 (77.3) | 44 (95.7) | 31 (67.4) | |
Moderate | 17 (17.5) | 2 (4.3) | 15 (32.6) | |
severe | 0 (0) | 0 (0) | 0 (0) | |
Intubation, n (%) | 5 (5) | 3 (6) | 2 (4) | 0.6 |
Mechanical Ventilation, n (%) | 5 (5) | 3 (6) | 2 (4) | 0.6 |
Mortality, n (%) | 3 (3) | 1 (2) | 2 (4) | 0.5 |
Medication side effect, n (%) | 15 (100) | 3 (100) | 12 (100) | 0.1 |
Nausea/vomiting, n (%) | 8 (53.5) | 1 (33.3) | 7 (58.3) | |
Dizziness, n (%) | 3 (20) | 0 (0) | 3 (25) | |
Others, n (%) | 4 (26.7) | 2 (66.7) | 2 (16.7) | |